<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9687">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692531</url>
  </required_header>
  <id_info>
    <org_study_id>R34MH121295</org_study_id>
    <nct_id>NCT05692531</nct_id>
  </id_info>
  <brief_title>Evaluation of A Story Within A Story: The Novel CHHARGE Intervention Component</brief_title>
  <acronym>CHHARGE</acronym>
  <official_title>Optimizing Study Design to Test a Community-level Intervention to Reduce Intersectional Stigma and Increase HIV Testing and Prevention Among African-American/Black MSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City University of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>City University of New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using a quasi-experimental evaluation approach, the purpose of this study is to assess&#xD;
      feasibility, acceptability, and preliminary efficacy of a novel community-level intervention&#xD;
      component, which is a filmed dramatization or set of &quot;scenarios&quot; to be &quot;screened&quot; in a&#xD;
      virtual event. Attendees will be polled and engaged in an evaluation of the scenarios, before&#xD;
      during and after the screening. This NCT registration is for the final aim of the study as&#xD;
      described in the detailed description (AIMS) below. (Please note Aims 1-2 are complete.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing access to and uptake of consistent HIV testing and biomedical prevention is&#xD;
      critical to ending the epidemic in the United States (US) among gay, bisexual and other men&#xD;
      who have sex with other men (MSM). This is particularly true for urban,&#xD;
      African-American/Black MSM, who are disproportionately affected by HIV/AIDS in the US2-4 and&#xD;
      would thus benefit from consistent testing, which is the gateway to treatment and prevention.&#xD;
      NYC is the metropolitan area in the US with the largest number of newly diagnosed HIV&#xD;
      infections among MSM and 89-94% of all people living with HIV/AIDS (PLWHA) in the US reside&#xD;
      in urban areas. HIV stigma is a key barrier to HIV treatment and prevention, reducing access&#xD;
      to testing and anti-retroviral treatment (ART). Stigmas specific to biomedical prevention&#xD;
      (e.g., PrEP/PEP stigma) and HIV testing have emerged and influence intentions to use PrEP/PEP&#xD;
      and testing. In addition, homophobia has been identified as a barrier to prevention access,&#xD;
      with structural homophobia negatively associated with PEP awareness and PrEP use.&#xD;
      Intersectional HIV-related stigmas and homophobia may be especially significant barriers to&#xD;
      HIV testing and prevention among African-American/Black MSM, who test less often and are more&#xD;
      likely to live with undiagnosed HIV/AIDS compared with white MSM. African-American/Black MSM&#xD;
      live in a racist society, which operates at the personal and institutional levels. This&#xD;
      results in experiences of HIV-related stigma and homophobia being racialized, further&#xD;
      inhibiting access to and uptake of testing, prevention and treatment.&#xD;
&#xD;
      Interventions to decrease HIV stigma have aimed primarily at the individual level and on&#xD;
      internalized stigma and/or personal attitudes, providing education and increased contact with&#xD;
      PLWHA to reduce stereotyping and active discrimination. Few have addressed HIV stigma and&#xD;
      homophobia simultaneously or at the community level. One exception, designed and evaluated by&#xD;
      study team leaders, Frye &amp; Taylor-Akutagawa, is CHHANGE (Challenge HIV/AIDS Stigma &amp;&#xD;
      Homophobia and Gain Empowerment; R21 MH102182-01; PI: Frye), a community-level, theory-based,&#xD;
      anti-stigma and -homophobia intervention. Designed for African-American urban neighborhoods&#xD;
      with high HIV prevalence, and broadly framed within socioecological, empowerment and stigma&#xD;
      theories, CHHANGE focused on: enhancing visibility; increasing contact with LGBTQ people and&#xD;
      PLWHA; educating on stigmatization processes and effects; enhancing empathy and&#xD;
      perspective-taking; challenging stereotyped beliefs; raising critical consciousness; and&#xD;
      teaching skills to analyze and interrupt stigma &amp; homophobia in organizations, families and&#xD;
      individuals. Results of the quasi-experimental, matched-community study found that HIV&#xD;
      testing increased by 350% at the intervention community site, though changes in&#xD;
      community-level HIV stigma and homophobia were not statistically significant across&#xD;
      communities.&#xD;
&#xD;
      The emergence of PEP/PrEP and testing stigmas highlight a gap in our HIV testing and&#xD;
      prevention toolbox for MSM of color and a need for interventions that address intersectional&#xD;
      stigmas. To our knowledge, no intervention addresses intersectional HIV, PrEP/PEP, testing&#xD;
      stigmas, and homophobia, in the context of racism. To address this gap, the investigators&#xD;
      propose an R34 to adapt and enhance CHHANGE to simultaneously address intersectional stigmas&#xD;
      and plan a trial to test the community-level intervention.&#xD;
&#xD;
      The Specific Aims are:&#xD;
&#xD;
        1. Inform design of novel components specific to PrEP/PEP and testing stigma. The&#xD;
           investigators will conduct group model building (GMB), a systems science technique, with&#xD;
           community residents and African-American/Black MSM (N=80) to understand the&#xD;
           intersectional complexity of HIV-related stigmas, homophobia, and racism, in context,&#xD;
           and identify novel levers that may influence consistent HIV testing and prevention&#xD;
           uptake.&#xD;
&#xD;
        2. Systematically adapt the CHHANGE intervention to integrate novel anti-stigma,&#xD;
           -homophobia, and -racism content and activities (re-named CHHARGE: Challenge HIV Stigma,&#xD;
           Homophobia and Racism and Gain Empowerment) and plan a pilot using optimal study design&#xD;
           methods. The investigators will ideate, prototype and component test (N=30), using&#xD;
           design thinking and traditional adaptation methods, novel modules and components in the&#xD;
           community. With input from a Senior Advisory Board (SAB), the investigators will&#xD;
           identify optimal study design features (around areal boundaries, &quot;big data&quot; outcome&#xD;
           measures, sampling, contamination, lagged effects) for planning a trial of the&#xD;
           community-level intervention (e.g., a community cluster randomized trial).&#xD;
&#xD;
        3. Assess feasibility, acceptability, and preliminary efficacy of novel component. The&#xD;
           investigators will conduct a quasi-experimental evaluation to assess feasibility of the&#xD;
           novel component. The investigators will assess preliminary efficacy of the component in&#xD;
           reducing community-level stigmas (HIV, PrEP/PEP, testing) by increasing likelihood of&#xD;
           engaging in stigma interrupting communication and behavior, particularly as related to&#xD;
           the theoretical targets identified via Phases 1 and 2, as well as likelihood of&#xD;
           consistent HIV testing and PrEP/PEP uptake.&#xD;
&#xD;
      Thus far, the research has completed phases 1 and 2 in partnership with Mobilizing Our&#xD;
      Brother Initiative (MOBI) creating an innovative module that facilitates consistent HIV&#xD;
      testing, and access to, uptake of and adherence to new biomedical HIV prevention modalities,&#xD;
      with the goal of lowering community-level viral load and ultimately a diminution of the HIV&#xD;
      epidemic among urban, Black MSM in the US.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an evaluation of a virtual event. The investigators will conduct a social media metrics analysis (of the social media-based run-up to the event as well as the actual event) via responses to polls embedded within the social media-based run-up, and sentiment assessment and analysis during the event itself. The investigators will conduct &quot;flash polls&quot; during the event using sentiments that reflect key stigmatization process-related aspects of the scenarios being depicted, for example asking attendees to rate the actors on specific qualities on a scale of 1 to 10 (for example, &quot;respect&quot; &quot;admire&quot; &quot;dislike&quot; &quot;annoyed&quot; &quot;tactful&quot; &quot;sensitive&quot; &quot;shady&quot; etc.); the investigators will repeat this after the scenarios are screened and integrate the immediate results into the discussion of the filmed scenarios. The investigators will conduct flash polls on confidence confronting stigmatizing language toward someone who is considering taking PrEP.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>internalized/anticipated HIV stigma</measure>
    <time_frame>immediately post-intervention</time_frame>
    <description>single-item, adapted, self-reported internalized/anticipated HIV stigma; we will use an item from Sayles et al (2008) valid and reliable measure of internalized/anticipated stigma (for example &quot;I am living with HIV and feel ashamed when I tell people that I have HIV/I am not living with HIV but would feel ashamed if I had to tell people that I have HIV&quot;). This item is adapted from Sayles, J. N., Hays, R. D., Sarkisian, C. A., Mahajan, A. P., Spritzer, K. L., &amp; Cunningham, W. E. (2008). Development and psychometric assessment of a multidimensional measure of internalized HIV stigma in a sample of HIV-positive adults. AIDS and Behavior, 12(5), 748-758.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>internalized homophobia</measure>
    <time_frame>immediately post-intervention</time_frame>
    <description>single-item, self-reported internalized HIV stigma; we will use items from a valid and reliable measure of internalized homophobia (Smolenski et al 2010; for example &quot;I would change myself to be heterosexual, if I could&quot;) From: Smolenski, D. J., Diamond, P. M., Ross, M. W., &amp; Rosser, B. S. (2010). Revision, criterion validity, and multigroup assessment of the Reactions to Homosexuality Scale. Journal of Personality Assessment,92, 568-576</description>
  </primary_outcome>
  <primary_outcome>
    <measure>internalized/anticipated PrEP stigma</measure>
    <time_frame>immediately post-intervention</time_frame>
    <description>single-item, self-reported PrEP stigma; we will use an item from a measure of PrEP stigma (Frye et al 2020) (for example &quot;People who who use PrEP are having too much sex or sex with the wrong kinds of people&quot;) From: Chittamuru, D., Frye, V., Koblin, B. A., Brawner, B., Tieu, H. V., Davis, A., &amp; Teitelman, A. M. (2020). PrEP stigma, HIV stigma, and intention to use PrEP among women in New York City and Philadelphia. Stigma and health, 5(2), 240.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV testing stigma</measure>
    <time_frame>immediately post-intervention</time_frame>
    <description>single-item, self-reported HIV testing stigma; we will use an item adapted from a measure of HIV testing stigma (for example &quot;if people know I get HIV tests frequently, they will think I am promiscuous or am having sex with men&quot;) From: Andrinopoulos, K., Hembling, J., Guardado, M. E., de Maria Hern√°ndez, F., Nieto, A. I., &amp; Melendez, G. (2015). Evidence of the negative effect of sexual minority stigma on HIV testing among MSM and transgender women in San Salvador, El Salvador. AIDS and Behavior, 19(1), 60-71.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intersectional Stigma</condition>
  <arm_group>
    <arm_group_label>A Story Within A Story</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single event that will be evaluated using quasi-experimental design methods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>A Story Within A Story</intervention_name>
    <description>The intervention is the screening via Zoom of &quot;A Story Within A Story,&quot; two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use.</description>
    <arm_group_label>A Story Within A Story</arm_group_label>
    <other_name>CHHARGE novel component</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all attendees of the event&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victoria Frye, DrPH</last_name>
    <phone>6464186435</phone>
    <email>VFrye@med.cuny.edu</email>
  </overall_contact>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 22, 2022</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>January 19, 2023</last_update_submitted>
  <last_update_submitted_qc>January 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>City University of New York</investigator_affiliation>
    <investigator_full_name>Victoria Frye</investigator_full_name>
    <investigator_title>Medical Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Because this is a quasi-experimental evaluation of an event, it is unclear if the data would be of any use to any other researchers other than this team.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

